Management of antineutrophil cytoplasmic antibody-Associated vasculitis with COVID-19: A single center experience
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients particularly presenting as rapidly progressive glomerulonephritis (RPGN) are at extremely high risk of progressing to end-stage kidney disease (ESKD); therefore, timely intervention is important. We describe our experien...
Gespeichert in:
| Veröffentlicht in: | Indian journal of nephrology 2023-01, Vol.33 (1), p.50-53 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 53 |
|---|---|
| container_issue | 1 |
| container_start_page | 50 |
| container_title | Indian journal of nephrology |
| container_volume | 33 |
| creator | Latief, Muzamil Mir, Tajamul Wani, Mohd |
| description | Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients particularly presenting as rapidly progressive glomerulonephritis (RPGN) are at extremely high risk of progressing to end-stage kidney disease (ESKD); therefore, timely intervention is important. We describe our experience of managing six AAV patients who were on treatment (induction phase) and developed COVID-19. Cyclophosphamide was stopped till RT-PCR for SARS-CoV-2 was reported negative and patient had improved symptomatically. Out of our six patients, one died. Subsequently, cyclophosphamide was successfully resumed in all the surviving patients. In patients of AAV with COVID-19, close monitoring and withholding of cytotoxic medication and continuing steroids till active infection subsides is an effective treatment strategy until more and more data from well-conducted largescale studies become available for guidance. |
| doi_str_mv | 10.4103/ijn.ijn_423_21 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10185014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A744964003</galeid><sourcerecordid>A744964003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495e-39bf730fb4a6040cddf899361aaa687cfa19d93583e45a038a5649a884f88f473</originalsourceid><addsrcrecordid>eNp1kt1vFCEUxYnR2LX66qMhMfFtVhiYD3wxm_WrSU1f1FfCMpcdtixMYabr_vey2nbbpIYQEu65vxwuB6HXlMw5Jey93fh53pKXTJb0CZpRIdqC1XX5FM2IaGjBSV2doBcpbQgpKy6q5-iENVQ0pCIzdPVdebWGLfgRB4OVH62HaYxh6K3Dej-Gwam0tfpvaRW6fbFIKWirRujwtUp6cna0Ce_s2OPlxa-zTwUVH_ACJ-vXDrDOZIgYfg8QLXgNL9Ezo1yCVzfnKfr55fOP5bfi_OLr2XJxXujsEQomVqZhxKy4qgknuutMKwSrqVKqbhttFBWdYFXLgFeKsFZVNReqbblpW8Mbdoo-_uMO02oL3cFHVE4O0W5V3MugrHxY8baX63AtKaFtRSjPhLc3hBiuJkij3IQp-mxalo3gvMmGyFG1Vg6k9SZkmt7apOWi4VzUnBCWVfNHVHl1kIcbPBib7x80vLvX0INyY5-Cm0YbfHqUrGNIKYK5eyIl8pARecjHMSO54c39wdzJb0NxnNwuuPx36dJNO4gyay992P0HKysib7PE_gA-es8Z</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2794478990</pqid></control><display><type>article</type><title>Management of antineutrophil cytoplasmic antibody-Associated vasculitis with COVID-19: A single center experience</title><source>Medknow Open Access Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Latief, Muzamil ; Mir, Tajamul ; Wani, Mohd</creator><creatorcontrib>Latief, Muzamil ; Mir, Tajamul ; Wani, Mohd</creatorcontrib><description>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients particularly presenting as rapidly progressive glomerulonephritis (RPGN) are at extremely high risk of progressing to end-stage kidney disease (ESKD); therefore, timely intervention is important. We describe our experience of managing six AAV patients who were on treatment (induction phase) and developed COVID-19. Cyclophosphamide was stopped till RT-PCR for SARS-CoV-2 was reported negative and patient had improved symptomatically. Out of our six patients, one died. Subsequently, cyclophosphamide was successfully resumed in all the surviving patients. In patients of AAV with COVID-19, close monitoring and withholding of cytotoxic medication and continuing steroids till active infection subsides is an effective treatment strategy until more and more data from well-conducted largescale studies become available for guidance.</description><identifier>ISSN: 0971-4065</identifier><identifier>EISSN: 1998-3662</identifier><identifier>DOI: 10.4103/ijn.ijn_423_21</identifier><identifier>PMID: 37197050</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Antibodies ; Care and treatment ; Case Series ; Chronic kidney failure ; COVID-19 ; Cyclophosphamide ; Cytoplasm ; Health aspects ; Kidney diseases ; Vasculitis ; Viral antibodies</subject><ispartof>Indian journal of nephrology, 2023-01, Vol.33 (1), p.50-53</ispartof><rights>Copyright: © 2022 Indian Journal of Nephrology.</rights><rights>COPYRIGHT 2023 Medknow Publications and Media Pvt. Ltd.</rights><rights>2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2022 Indian Journal of Nephrology 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c495e-39bf730fb4a6040cddf899361aaa687cfa19d93583e45a038a5649a884f88f473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185014/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185014/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27458,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37197050$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Latief, Muzamil</creatorcontrib><creatorcontrib>Mir, Tajamul</creatorcontrib><creatorcontrib>Wani, Mohd</creatorcontrib><title>Management of antineutrophil cytoplasmic antibody-Associated vasculitis with COVID-19: A single center experience</title><title>Indian journal of nephrology</title><addtitle>Indian J Nephrol</addtitle><description>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients particularly presenting as rapidly progressive glomerulonephritis (RPGN) are at extremely high risk of progressing to end-stage kidney disease (ESKD); therefore, timely intervention is important. We describe our experience of managing six AAV patients who were on treatment (induction phase) and developed COVID-19. Cyclophosphamide was stopped till RT-PCR for SARS-CoV-2 was reported negative and patient had improved symptomatically. Out of our six patients, one died. Subsequently, cyclophosphamide was successfully resumed in all the surviving patients. In patients of AAV with COVID-19, close monitoring and withholding of cytotoxic medication and continuing steroids till active infection subsides is an effective treatment strategy until more and more data from well-conducted largescale studies become available for guidance.</description><subject>Antibodies</subject><subject>Care and treatment</subject><subject>Case Series</subject><subject>Chronic kidney failure</subject><subject>COVID-19</subject><subject>Cyclophosphamide</subject><subject>Cytoplasm</subject><subject>Health aspects</subject><subject>Kidney diseases</subject><subject>Vasculitis</subject><subject>Viral antibodies</subject><issn>0971-4065</issn><issn>1998-3662</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kt1vFCEUxYnR2LX66qMhMfFtVhiYD3wxm_WrSU1f1FfCMpcdtixMYabr_vey2nbbpIYQEu65vxwuB6HXlMw5Jey93fh53pKXTJb0CZpRIdqC1XX5FM2IaGjBSV2doBcpbQgpKy6q5-iENVQ0pCIzdPVdebWGLfgRB4OVH62HaYxh6K3Dej-Gwam0tfpvaRW6fbFIKWirRujwtUp6cna0Ce_s2OPlxa-zTwUVH_ACJ-vXDrDOZIgYfg8QLXgNL9Ezo1yCVzfnKfr55fOP5bfi_OLr2XJxXujsEQomVqZhxKy4qgknuutMKwSrqVKqbhttFBWdYFXLgFeKsFZVNReqbblpW8Mbdoo-_uMO02oL3cFHVE4O0W5V3MugrHxY8baX63AtKaFtRSjPhLc3hBiuJkij3IQp-mxalo3gvMmGyFG1Vg6k9SZkmt7apOWi4VzUnBCWVfNHVHl1kIcbPBib7x80vLvX0INyY5-Cm0YbfHqUrGNIKYK5eyIl8pARecjHMSO54c39wdzJb0NxnNwuuPx36dJNO4gyay992P0HKysib7PE_gA-es8Z</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Latief, Muzamil</creator><creator>Mir, Tajamul</creator><creator>Wani, Mohd</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Scientific Scholar</general><general>Wolters Kluwer - Medknow</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20230101</creationdate><title>Management of antineutrophil cytoplasmic antibody-Associated vasculitis with COVID-19: A single center experience</title><author>Latief, Muzamil ; Mir, Tajamul ; Wani, Mohd</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495e-39bf730fb4a6040cddf899361aaa687cfa19d93583e45a038a5649a884f88f473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Care and treatment</topic><topic>Case Series</topic><topic>Chronic kidney failure</topic><topic>COVID-19</topic><topic>Cyclophosphamide</topic><topic>Cytoplasm</topic><topic>Health aspects</topic><topic>Kidney diseases</topic><topic>Vasculitis</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Latief, Muzamil</creatorcontrib><creatorcontrib>Mir, Tajamul</creatorcontrib><creatorcontrib>Wani, Mohd</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Indian journal of nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Latief, Muzamil</au><au>Mir, Tajamul</au><au>Wani, Mohd</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of antineutrophil cytoplasmic antibody-Associated vasculitis with COVID-19: A single center experience</atitle><jtitle>Indian journal of nephrology</jtitle><addtitle>Indian J Nephrol</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>33</volume><issue>1</issue><spage>50</spage><epage>53</epage><pages>50-53</pages><issn>0971-4065</issn><eissn>1998-3662</eissn><abstract>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients particularly presenting as rapidly progressive glomerulonephritis (RPGN) are at extremely high risk of progressing to end-stage kidney disease (ESKD); therefore, timely intervention is important. We describe our experience of managing six AAV patients who were on treatment (induction phase) and developed COVID-19. Cyclophosphamide was stopped till RT-PCR for SARS-CoV-2 was reported negative and patient had improved symptomatically. Out of our six patients, one died. Subsequently, cyclophosphamide was successfully resumed in all the surviving patients. In patients of AAV with COVID-19, close monitoring and withholding of cytotoxic medication and continuing steroids till active infection subsides is an effective treatment strategy until more and more data from well-conducted largescale studies become available for guidance.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>37197050</pmid><doi>10.4103/ijn.ijn_423_21</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0971-4065 |
| ispartof | Indian journal of nephrology, 2023-01, Vol.33 (1), p.50-53 |
| issn | 0971-4065 1998-3662 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10185014 |
| source | Medknow Open Access Journals; PubMed Central; EZB Electronic Journals Library |
| subjects | Antibodies Care and treatment Case Series Chronic kidney failure COVID-19 Cyclophosphamide Cytoplasm Health aspects Kidney diseases Vasculitis Viral antibodies |
| title | Management of antineutrophil cytoplasmic antibody-Associated vasculitis with COVID-19: A single center experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A35%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20antineutrophil%20cytoplasmic%20antibody-Associated%20vasculitis%20with%20COVID-19:%20A%20single%20center%20experience&rft.jtitle=Indian%20journal%20of%20nephrology&rft.au=Latief,%20Muzamil&rft.date=2023-01-01&rft.volume=33&rft.issue=1&rft.spage=50&rft.epage=53&rft.pages=50-53&rft.issn=0971-4065&rft.eissn=1998-3662&rft_id=info:doi/10.4103/ijn.ijn_423_21&rft_dat=%3Cgale_pubme%3EA744964003%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2794478990&rft_id=info:pmid/37197050&rft_galeid=A744964003&rfr_iscdi=true |